Table 3 Neoadjuvant treatment-related adverse events
Any grades | Grade 1–2 | Grade 3 | Grade 4 | |
|---|---|---|---|---|
Diarrhea | 17 (68%) | 12 (48%) | 5 (20%) | 0 |
Rash | 15 (60%) | 12 (48%) | 3 (12%) | 0 |
Mucositis | 10 (40%) | 9 (36%) | 1 (4%) | 0 |
Pruritus | 10 (40%) | 9 (36%) | 1 (4%) | 0 |
Hypoproteinemia | 8 (32%) | 8 (32%) | 0 | 0 |
Paronychia | 8 (32%) | 8 (32%) | 0 | 0 |
Hypokalemia | 8 (32%) | 4 (16%) | 4 (16%) | 0 |
Poor appetite | 5 (20%) | 3 (12%) | 2 (8%) | 0 |
Hyponatremia | 4 (16%) | 4 (16%) | 0 | 0 |
Hypocalcemia | 3 (12%) | 3 (12%) | 0 | 0 |
Serum creatinine increase | 3 (12%) | 3 (12%) | 0 | 0 |
Hypothyroidism | 3 (12%) | 3 (12%) | 0 | 0 |
ALT increase | 3 (12%) | 2 (8%) | 1 (4%) | 0 |
AST increase | 3 (12%) | 2 (8%) | 1 (4%) | 0 |
Troponin T increases | 2 (8%) | 2 (8%) | 0 | 0 |
Dysgeusia | 2 (8%) | 2 (8%) | 0 | 0 |
Nausea | 1 (4%) | 1 (4%) | 0 | 0 |
Hyperuricemia | 1 (4%) | 1 (4%) | 0 | 0 |
Hypophosphatemia | 1 (4%) | 1 (4%) | 0 | 0 |
Constipation | 1 (4%) | 1 (4%) | 0 | 0 |
Bilirubin increase | 1 (4%) | 1 (4%) | 0 | 0 |
Pneumonitis | 1 (4%) | 0 | 1 (4%) | 0 |
